Stifel raised the firm’s price target on Revolution Medicines (RVMD) to $80 from $70 and keeps a Buy rating on the shares. The firm notes that today’s results didn’t show the expected 300mg RMC-6236 dose as being efficacious and tolerable with pembro, which is why Stifel thinks the stock is soft. But the data for 200mg outline solid efficacy and argue for an additive effect on top of pembro, and the firm thinks should beat 1L NSCLC SoC. The RMC/pembro datasets look benign from a liver tox perspective, though some may push back on the short follow-up time. However, Stifel is optimistic as we’ve historically seen liver tox emerge as an early event in other KRASi/pembro 1L NSCLC studies. At this valuation, the firm thinks investors are sensitive to downside risk, and are thus skeptical of data outside of expectations. While RMC-6236 was required to be dosed down in NSCLC, efficacy looks good, setting up Revolution to now pursue a large 1L NSCLC opportunity, Stifel says.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on RVMD:
- Revolution Medicines provides updates from RAS(ON) inhibitor combo studies
- Revolution Medicines provides updates from RAS(ON) inhibitor portfolio
- Erasca initiated with a Buy at Jefferies
- Revolution Medicines price target raised to $70 from $57 at Piper Sandler
- Revolution Medicines price target raised to $72 from $60 at Barclays
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
